the ability to isolate, expand and differentiate adult stem cells into a chondrogenic lineage is an important step in the development of tissue engineering approaches for cartilage repair or regeneration for the treatment of joint injury or osteoarthritis, as well as for their application in plastic or reconstructive surgery. adipose-derived stem cells (ascs) provide an abundant and easily accessible source of adult stem cells for use in such regenerative approaches. this protocol first describes the isolation of ascs from liposuction aspirate. the cell culture conditions provided for asc expansion provide a large number of multipotent stem cells. Instructions for growth factor-based induction of ascs into chondrocyte-like cells using either cell pellet or alginate bead systems are detailed. these methods are similar to those published for chondrogenesis of bone marrow-derived mesenchymal stem cells but distinct because of the unique nature of ascs. Investigators can expect consistent differentiation of ascs, allowing for slight variation as a result of donor and serum lot effects. approximately 10-12 weeks are needed for the entire process of asc isolation, including the characterization of chondrocyte-like cells, which is also described.
IntroDuctIon
The treatment of pathologies in articular and elastic cartilage poses important unmet challenges to the medical community. For example, arthritis represents the most common cause of disability in the United States, leading to joint pain and dysfunction in over 40 million Americans 1, 2 . Osteoarthritis, the most common form, involves degeneration of the articular cartilage-the smooth, load-bearing tissue lining the ends of long bones within the synovial joints of the body. The greatest risk factors for osteoarthritis include aging, obesity, joint trauma and mutations in cartilage-specific matrix proteins 3 . Current estimates of treatment costs, both indirect and direct, of osteoarthritis in the United States are greater than $65 billion annually 4 . For plastic and reconstructive surgery in the head and neck area, elastic cartilage is often needed, particularly in nose, ear and trachea reconstruction 5 . Estimates of the number of US procedures involving bone and cartilage replacement exceed one million per year 6 .
Cartilage properties and current treatment options
The unique function and properties of cartilage are provided by the tissue's extracellular matrix, which is maintained by a population of cells known as chondrocytes. Because of its small volume of chondrocytes (2-5% by volume), as well as its avascular and aneural properties, cartilage exhibits little to no intrinsic repair capabilities in response to injury or disease. Traditional efforts to treat cartilage damage include joint lavage, tissue debridement, microfracture of the subchondral bone, abrasion arthroplasty or the transplantation of autologous or allogeneic osteochondral grafts [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Although these procedures have yielded promising clinical results, they are generally not applicable for large cartilage defects or for degenerative joint diseases such as osteoarthritis [18] [19] [20] . One tissue engineering approach, autologous chondrocyte transplantation, has shown promising results in early clinical reports 21, 22 , but recent, randomized, controlled trials suggest little difference in the efficacy of this procedure over microfracture of the subchondral bone 23 . In this regard, there has been significant interest in the development of new tissue engineering strategies for the repair or replacement of damaged or diseased cartilage, and integral to such approaches is the need for an abundant and easily accessible source of cells. Although most early attempts at cartilage tissue engineering have relied on the use of primary differentiated chondrocytes, it is important to note that there are many issues associated with the harvest of autologous tissue and cells for cartilage repair. Among these are the disease state of the harvested cells (from the inflamed joint), the potential for initiation of osteoarthritic changes in the joint 23, 24 , the lack of adequate autogenous tissue and the difficulty in expanding the cells ex vivo while maintaining the chondrocyte phenotype 25, 26 . These issues provide significant barriers to the use of autogenous primary chondrocytes for successful cartilage repair treatment strategies. Currently, defects in the head and neck area are typically treated with autologous cartilage, usually harvested from costal cartilage grafts 27 . Advantageously, the use of autologous tissues presents an implant that can be formed in the correct anatomical shape without risk of immunological rejection. However, the limitations and potential disadvantages of autologous tissue use are noteworthy and include the lack of available tissue for large defects, the risk of iatrogenic deformity and significant donor-site morbidity 27, 28 .
Stem cells in cartilage repair
The use of adult stem cells presents a viable alternative for cartilage repair strategies and has the potential for success while avoiding the issues associated with autogenous grafts and/or cells. Mesenchymal stem cells (MSCs) from bone marrow have been shown to possess multilineage differentiation potential and have been characterized extensively for a variety of tissue engineering applications including chondrogenesis [29] [30] [31] . Another multipotent adult stem cell population, ASCs, can easily be obtained from liposuction waste 32, 33 and has been shown in numerous studies to exhibit the potential for chondrogenesis, osteogenesis, adipogenesis, myogenesis and some aspects of neurogenesis [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Although these cells show some similarities to bone marrow MSCs, they appear to have a number of distinct characteristics with respect to their cell surface markers, differentiation potential and abundance in the body. For example, compared with 100 ml of bone marrow aspirate, up to 300-fold more stem cells can be obtained from 100 g of adipose tissue 31, 46 .
Adipose-derived stem cells have shown significant potential for chondrogenic differentiation when expanded in appropriate monolayer conditions 47 and cultured in growth factor-containing medium in 3D culture [34] [35] [36] 43, 45 . As it was originally hypothesized that ASCs were another source of MSCs, similar conditions used to induce chondrogenesis in MSCs 31 were used for the ASC population 36, 43 . In optimizing ASC differentiation protocols, it was later discovered that other members of the transforming growth factor-β (TGF-β) superfamily, such as bone morphogenetic protein 6 (BMP-6), can serve as potent regulators of ASC chondrogenesis 45, 48 . In general, chondrogenesis requires a 3D culture system, and ASCs can be successfully induced down a chondrogenic lineage in a variety of scaffold environments. These culture configurations include pellet culture, which takes advantage of cell-cell interactions in a manner similar to condensation during cartilage development 49 , alginate bead culture, which uses an inert hydrogel to facilitate a rounded cell phenotype advantageous for chondrogenesis 36 , and cartilage-derived matrix, which seeks to recapitulate some of the cell-matrix interactions seen in native cartilage 50, 51 . To repair or regenerate articular cartilage, an understanding of the molecular constituents and their role in the mechanical function of cartilage must be taken into consideration. Articular cartilage provides joint congruity and a lubricated surface for articulation, effectively distributing loads of up to 10 times the body weight that pass through the joint during normal physiological activity 52 . Remarkably, this tissue provides a nearly frictionless bearing surface for the joint, and functions over decades of use with little or no wear under normal circumstances. Articular cartilage is > 60% collagen by dry weight 52, 53 , primarily consisting of collagen type II with lesser amounts of other collagens (for example, types VI, IX, X and XI). The collagen fibrils are located throughout the matrix and are intertwined with a highly concentrated negatively charged proteoglycan matrix 54, 55 . Two primary glycosaminoglycans (GAGs) are found in articular cartilage; namely, chondroitin sulfate and keratin sulfate. GAG side chains (polymer repeats of the sulfated molecule) are found assembled covalently to a protein core to form a proteoglycan aggregate (reviewed in ref. 54) . The large aggregating proteoglycan aggrecan is assembled into a complex structure by noncovalent linkage of proteoglycan aggregates to a hyaluronate backbone, thus producing immobilized structures contributing to the articular cartilage solid matrix 53 . The assembly of the cartilage matrix gives the tissue its unique set of biomechanical properties by virtue of the ability of the collagen-proteoglycan matrix, together with the interstitial fluid, to effectively resist high levels of stress and strain engendered by normal loading of the joint. Although creating a true mimic of articular cartilage may not be necessary for proper function, a tissue possessing similar molecular constituents will most likely possess similar mechanical properties. Thus, monitoring the assembly and spatial organization of key extracellular matrix components is an important step in the development of tissue-engineered cartilage implants.
Markers of chondrogenesis
Herein, we report the methods for inducing chondrogenesis through ASC isolation and expansion, scaffold preparation and cell encapsulation under appropriate biochemical conditions. See Figure 1 for a flow chart showing the procedure and associated timing information. We further report methods used to evaluate the degree of chondrogenic differentiation in 3D culture (Table 1) .
Controls
We have previously shown that approximately 43% of ASCs at a clonal level are capable of chondrogenic differentiation 37 . Because of this, it is relatively straightforward to select cells that have both high and low chondrogenic differentiation potential, which can be used for positive and negative controls, respectively. Moreover, in most circumstances, ASCs can be cultured in a control medium without growth factors as negative controls 45, 51, 56, 57 . Specifically, as relates to histology and immunohistochemistry (IHC), sections of articular cartilage should be used as positive controls to assess the degree of chondrogenic differentiation of the tissue-engineered constructs.
Appropriate selection of an ASC culture system
In this protocol, we describe two commonly used 3D culture systems that can be used to chondrogenically induce ASCs. Although both these culture systems have been successfully used for ASC chondrogenesis, the selection of one over the other depends highly on the study purposes. The use of pellet culture results in high spatial cell density and necessitates cell-cell contact, similar to the cellular condensation process during limb development 49 . Alternatively, the use of alginate results in a rounded cell morphology, similar to that observed in articular cartilage, which has also been shown to be an important factor in promoting ASC chondrogenesis 36 . The use of pellet culture mimics the development of cartilage during limb formation and is therefore often used as a method for understanding how the interaction of cells, growth factors and environmental factors promotes a chondrogenic phenotype 37, 48, 58, 59 . Although alginate can also be used for this purpose 35, 36, 51, 56, 60 , the use of alginate and other hydrogels can have profound influences on the ensuing cell phenotypes 35, 50, 61 . Therefore, the effect of the biomaterial as a significant variable influencing the differentiation potential of the cells must be taken into account when choosing an appropriate culture system. It is also important to note that, although we report on the methods for two often-used cell culture systems, many other materials and culture systems have been reported as being supportive of ASC chondrogenesis 35, 50, 62 and should also be considered when selecting an ASC culture system. Regardless of the culture system used, the methods for inducing chondrogenesis with the growth factors discussed herein may still serve as a common starting ground for ASC chondrogenesis. • Table 3 . Expansion medium may be stored at 4 °C in the dark for up to 2 weeks. Stromal medium: Use all reagents listed in Table 3 , except for rhEGF, rhFGF and TGF-β1 (stromal medium should not contain any growth factors). Stromal medium may be stored at 4 °C in the dark for up to 6 weeks.
Collagenase solution: This should be prepared fresh before starting the isolation process, and filter sterilized using a 250-ml sterilization unit. Pre Cell differentiation Incomplete chondrogenic medium: Prepare the medium using all reagents listed in Table 4 . This medium may be stored at 4 °C in the dark for up to 6 weeks. Complete chondrogenic medium: Thaw growth factors and add freshly to incomplete chondrogenic medium just before use. Three different growth factor combinations have been used successfully to promote ASC chondrogenesis ( Table 5) . Alginate culture Preparation of 1.2% (wt/vol) alginate solution: Dissolve 1.2 g of alginate in 100 ml of 150 mM NaCl. Heat on a hot plate and stir thoroughly. Filter sterilize using a 0.22-µm filter. Another option is to prepare the solution using an aseptic technique in a sterile hood, thus obviating the need for filter sterilization. Store the resulting alginate solution (1.2%) at 4 °C.
Preparation of CaCl 2 (102 mM) solution: Take 10.2 ml of a 1 M CaCl 2 stock solution in a 100-ml volumetric flask and then pipet in 89.8 ml of dH 2 O. Filter through a 250-ml filter system. Store the working solution (102 mM) at 4 °C.
Preparation of NaCl (150 mM) solution: Take 15.0 ml of the 1 M NaCl stock solution in a 100-ml volumetric flask and then pipet in 85 ml of dH 2 O. Filter through a 250-ml filter system. Store the working solution (150 mM) at 4 °C.
Sodium chloride (50 mM)-sodium citrate (55 mM) buffer: Dissolve 1.461 g of NaCl in 300 ml of dH 2 O. Dissolve 8.087 g of sodium citrate into this same solution. Add dH 2 O to a final volume of 500 ml. Sample fixative for histology/IHC Pipet 10 ml of 16% paraformaldehyde into a 50-ml conical tube. Dissolve 0.856 g of sodium cacodylate. If alginate is being fixed, add 0.104 g of BaCl 2 to irreversibly cross-link the alginate matrix. Titrate the solution with 1 N HCl to adjust the pH to 7.4. Adjust the final volume of the solution to 40 ml with dH 2 O. ! cautIon Paraformaldehyde and sodium cacodylate are considered carcinogenic. Handle these reagents only in a biosafety level 3 cabinet with the sash adjusted to the proper height to provide maximum protection to the user. DMB assay Preparation of DMB dye: Dissolve 21 mg of DMB into 5 ml of absolute ethanol with 2.0 g of sodium formate and stir thoroughly in 800 ml of dH 2 O. Titrate concentrated formic acid into the dye solution to adjust the pH to the desired level (pH 1.5 for the alginate DMB assay and pH 3.0 for the pellet cultures). Add dH 2 O to arrive at a final volume of 1,000 ml. This solution may be stored for up to 6 months at room temperature (RT, 19-25 °C). Note that the solution should be protected from light.
Preparation of stock chondroitin-4-sulfate standard solution (10 mg ml − 1 ): Weigh 100 mg of C-4-S. Dissolve the powder in 10 ml of D-PBS in a 50-ml conical tube. Vortex to ensure thorough mixing. Dilute 1 ml of the stock C-4-S solution in 9 ml of papain solution. This produces a 1 mg ml − 1 C-4-S solution. Freeze in 1-ml aliquots and store at − 80 °C. Thaw an aliquot on the day of the assay to prepare the standard curve for the DMB assay. OHP assay Preparation of acetate-citrate buffer (pH 6.5): Dissolve 12 g of sodium acetate trihydrate, 5 g of citric acid monohydrate, 1.2 ml of acetic acid and 3.4 g of sodium hydroxide in 750 ml of dH 2 O. Measure pH and adjust to 6.0 if necessary by titration with 1 N NaOH or acetic acid. Bring the solution to a final volume of 1,000 ml with dH 2 O. It can be prepared and stored for 1-2 months at RT.
Preparation of chloramine-T reagent (0.062 M): Dissolve 141 mg of chloramine-T in 2.07 ml of dH 2 O and 2.6 ml of n-propanol. Note: Mix dH 2 O and n-propanol first. Add 5.33 ml of the acetate-citrate buffer described above. Vortex to dissolve completely.  crItIcal Must be prepared fresh just before use.
Preparation of p-DMBA reagent (0.94 M): Dissolve 1.4 g of p-dimethylaminobenzaldehyde in 7 ml of n-propanol and vortex. Add 3.0 ml of perchloric acid. Vortex to dissolve completely.  crItIcal Must be prepared fresh just before use, and should be used within 1 h.
OHP standard stock (10 mg ml − 1 ): Dissolve 100 mg of trans-4 hydroxyproline-l in 10 ml of dH 2 O to obtain a stock solution of 10 mg ml − 1 . Vortex to dissolve completely. Can be prepared in advance and stored in 1-ml aliquots at − 80 °C. ? troublesHootInG
In addition, 37.5-50 µg ml − 1 l-ascorbic acid 2-phosphate is added freshly to overcome the instability of l-ascorbic acid 2-phosphate in culture medium. l-Ascorbic acid 2-phosphate stock (1,000×) can be made in DMEM-HG and stored in frozen aliquots for up to six weeks at − 20 °C. proceDure asc isolation • tIMInG 3-5 h 1| Prepare the shaker water bath at 37 °C, with enough water to cover the bottles containing collagenase mixture.
2|
Prepare fresh a solution of 0.1% (wt/vol) collagenase, 1% (vol/vol) BSA (Fraction V) and 2 mM calcium chloride in D-PBS. The volume of the collagenase solution should equal the volume of lipoaspirate to be processed (usually 100-200 ml).
3| Warm the D-PBS-collagenase solution and medium to 37 °C.
4| Allow the fat transport container to settle until the fat and blood are well separated. Transfer the fat to a sterile, 250-ml plastic centrifuge tube for separation. Note that cell isolations are routinely performed on the day of receipt or performed the next day after leaving the tissue at RT overnight. ! cautIon Procedures must be performed in accordance with institutional review board policies for obtaining human tissue, including informed consent by personnel certified and trained to work with blood-borne pathogens. All procedures involving human tissue should be performed at biosafety level 2 with appropriate personal protection.
5|
Using a 25-ml serological pipette, aspirate off the blood layer from beneath the floating fat.
6|
Check the tissue volume; it should be ~100 ml in each 250-ml centrifuge tube. Isolated cells will be plated at an equivalent of ~35 ml of liposuction aspirate digest per 225-cm 2 flask, so plan the amount of tissue needed accordingly. If there is less tissue volume, the flask size should be reduced accordingly to achieve ~0.16 ml of tissue per square centimeter.
7|
Wash the fat with D-PBS (1:1 volume) seven times or until the color of the D-PBS layer is about the hue of the fat-a light pink color. Allow the two phases to separate between washes (3-5 min). Gently stir the solution while it settles; this will encourage separation and aid in washing. Continue to remove the blood layer from beneath the yellow fat tissue. After a few washes (four should be sufficient), a bright yellow layer of extracellular fat will begin to form on top of the fat cell layer. Carefully aspirate off this thin layer.
8|
After the fat layer has been thoroughly washed, mix it in the ratio of 1:1 (vol/vol) with the warm D-PBS-collagenase solution. Place it in the 37 °C shaker water bath and gently shake for 1 h. Shake to mix by hand every 20 min if using 250-ml centrifuge bottles, or shake to mix by hand every 5-10 min if using 50-ml centrifuge tubes.
Note that if a shaker water bath is not available, 50-ml or 250-ml tubes may be placed on a shaker in a 37 °C incubator. ? troublesHootInG 9| Centrifuge at 300g at 21 °C for 5 min.
10| Shake the tubes vigorously for 10 s to ensure that individual cells are released from the strands of fibrous tissue.
11|
Centrifuge at 300g at 21 °C for 5 min.
12|
Aspirate off the floating mature adipocyte layer and the aqueous D-PBS-collagenase supernatants, leaving 5 ml of D-PBS on each pellet of cells. Be careful while handling the cell pellet, as it is gelatinous and does not adhere readily to the centrifuge tubes. ? troublesHootInG 13| Resuspend each cell pellet in 10 ml of stromal medium and pool the suspensions into sterile 50-ml centrifuge tubes.
14|
15|
Aspirate off the supernatants, leaving 5 ml of stromal medium on each pellet.
16|
Resuspend cell pellets in 10 ml of stromal medium and pool contents into sterile 50-ml centrifuge tubes.
17|
18|
Aspirate off the supernatants, leaving 5 ml of stromal medium on each pellet. Note that pellets can look very different from subject to subject at this stage.
19|
Resuspend in a total of 105 ml stromal medium per 100 ml of lipoaspirate digest. ? troublesHootInG asc expansion • tIMInG 2-5 weeks 20| Plate each dish at an equivalent density of 0.16 ml of liposuction aspirate per cm 2 or ~35 ml per 225-cm 2 flask.
21|
Thoroughly clean up by collecting all contaminated materials into biohazard bags.
22|
Clean the hood with 10% detergent, then with 10% bleach, followed by 70% ethanol.
23| After 24 h, change the medium on the cells to wash away any nonadherent cells. Representative images of ASCs through one passage can be seen in Figure 2 .  crItIcal step Cells may be used up to passage 4, after which the cells will start to lose their differentiation potential.
(ii) Trypsinize cells at ~80% confluence (Fig. 2g) . (ii) Resuspend ASCs in 1.2% alginate solution at 5 × 10 6 cells per ml in a 50-ml conical tube. Mix thoroughly by pipetting without creating bubbles, or mix with the use of micro stir bars using a magnetic stirring plate. Note that if the latter technique is used for mixing, a volume of greater than 700 µl is required to avoid creating bubbles. (iii) Using a 1-ml pipette, draw 1 ml of solution into the tip. (iv) Dispense by tilting the pipette sideways and slowly pipetting the cell suspension such that one drop falls from the pipette tip into 1 ml of prewarmed CaCl 2 . Typically, three drops of alginate are added to each well of a low attachment surface 24-well plate. (Fig. 3 shows a ×2.5 image of ASCs encapsulated within alginate.) Note that the alginate beads will vary in diameter from ~4 to 5 mm and will contain ~275,000 cells each. Five to six wells can be filled per ml of alginate. (v) Incubate the alginate beads at 37 °C for 5 min to allow Ca + 2 cations to fully diffuse through the alginate and cross-link the alginate cell suspension. (vi) Pipet off the CaCl 2 solution. Note that aspiration can be used, but care must be taken to avoid suction pressure on the alginate beads. (vii) Wash the beads with 1.5 ml of incomplete chondrogenic medium at 37 °C for 15 min. Pipet off the incomplete medium and repeat for an additional 15 min at 37 °C. (viii) Replace the incomplete medium with complete chondrogenic medium, 1 ml per well of a 24-well plate. Note that, typically, 1 ml of medium is used for every 800,000-1,000,000 cells. Incomplete chondrogenic medium can be used as a negative control. Complete chondrogenic medium with ASCs known to be capable of chondrogenesis may be used as a positive control. (ix) Incubate at 37 °C in 5.0% CO 2 . Depending on experimental design, take samples at day 0 and at subsequent time points to be prepared for biochemical examination, histological and immunohistological examination, or gene expression analysis. Accordingly, proceed to the applicable section of this protocol. Refer to Figure 1 for timing of procedures. Every other day for the duration of the experiment, prepare complete chondrogenic medium by adding growth factors and l-ascorbic acid 2-phosphate and exchange medium. Typical durations for culture are 2, 4 and 6 weeks.
? troublesHootInG table 3 for information about what each assay assesses. To perform the DMB assay 34, 35 , follow option A. To perform the OHP assay 35, 63, 64 , follow option B. To perform histology or IHC, proceed with option C for all samples, followed by option D for safranin-O/fast green staining, option E for toluidine blue staining or option F for IHC. To perform qPCR, follow option G. Note that it is likely that some or all samples will need to be diluted with papain at this stage for the samples to fall in the range of the standard curve. (iv) Aliquot 50 µl of the standard solutions and samples in prelabeled microcentrifuge tubes. Note that any dilutions that need to be carried out to bring samples within the range of the standard curve should be performed at this step using papain. If the corrected OD sample is negative, set it to zero (negative values indicate that the samples do not have any measurable s-GAG or OHP content, but because of interference the measured OD indicates a value less than zero). antIcIpateD results Adipose-derived stem cells can be expanded rapidly in a monolayer culture (Fig. 2) . After expansion, ASCs can be differentiated in pellet or alginate culture accordingly, using the induction cocktails listed in table 5. We have previously defined successful chondrogenesis using histological and biochemical markers. For pellet culture, one can anticipate successful chondrogenesis as having a s-GAG content ≥931.7 ± 222.3 ng per pellet and having collagen II present in ≥29.0 ± 2.2% of the area stained per field of view 37 . This metric is based on histogram-derived thresholds set at values exceeding the 90th percentile of controls for each assay 37 . Similar metrics can also be applied to hydrogel-based scaffold systems (for example, alginate) to discern the degree and success of chondrogenesis, although the reader is reminded that because of the negative charge of the alginate matrix, neither safranin-O nor toluidine blue may be used. Therefore, when using alginate, the user of this protocol must rely on IHC to discern the spatial organization of the cartilaginous matrix 45, 51, 56, 57 . Figure 4 shows the variability observed in the accumulation of a s-GAG matrix in pellet culture using toluidine blue, showing a positive result in Figure 4b , whereas Figure 4c is indicative of a poor or negative result for chondrogenesis. Similarly, under appropriate conditions, ASCs embedded in alginate synthesize collagens and proteoglycans (Fig. 5) , although negative markers of chondrogenesis (such as collagen I and excessive collagen X) should also be monitored. Typically, cartilage-specific matrix molecules are seen most intensely in the pericellular matrix with diffuse staining throughout the tissueengineered construct. During chondrogenic differentiation, it is also typical to observe a significant size increase in the pellet. This pellet size difference is observed as early as 14 d in culture and persists throughout the duration of the experiment (Fig. 6) .
In terms of biochemical content, typical standard curves for both the DMB and OHP assay are seen in Figure 7 . In general, we measure s-GAG and OHP content in the range of 4-10 µg per µg of dsDNA, as we have previously shown 34, 35 . Our qPCR analyses have typically been used to ascertain early chondrogenic events. For example, after 7 d in culture, the addition of 500 ng ml − 1 BMP-6 upregulated the expression of principal cartilage extracellular matrix components-aggrecan (AGC1) and type II collagen (COL2A1)-over that in day 0 controls by an average of 205-fold and 38-fold, respectively, although it downregulated the expression of type X collagen (COL10A1) expression by approximately twofold 45 . Clearly, qPCR data must be evaluated in concert with the other assays detailed in this protocol to determine chondrogenic efficiency. This is also true in general, as the achievement of a specific value or threshold, in terms of biochemical content or fold difference over control through qPCR analyses, does not necessarily indicate successful chondrogenesis. The degree and success of chondrogenic differentiation must ultimately be assessed by the investigator when viewed in terms of the hypothesis, the objectives, the chondrogenic culture system and the sum total of all assays used to assess chondrogenesis. 
